44 results on '"Xu, Lu"'
Search Results
2. Integrative analysis indicates the potential values of ANKRD53 in stomach adenocarcinoma
- Author
-
Chunjing Jin, Xu Lu, Minfeng Yang, and Shiqiang Hou
- Subjects
ANKRD53 ,Stomach adenocarcinoma ,Biomarker ,Prognosis ,Immunity ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Ankyrin repeat domain 53 (ANKRD53) plays an important role in maintaining chromosome integrity and stability, and chromosome instability is associated with cancer. Through integrative analysis, this study investigates the potential value of ANKRD53 in stomach adenocarcinoma (STAD). Methods RNA-seq and scRNA-seq data were used for integrative analysis based on online databases. Expression of ANKRD53 was confirmed by RT-PCR after bioinformatic analysis. Kaplan–Meier and Cox regression analyses were performed to evaluate the prognostic value of ANKRD53 in STAD. Gene set enrichment analysis (GSEA) was performed to evaluate ANKRD53-related signaling pathways. In addition, the interaction of ANKRD53 with immunity was also investigated. Results RT-PCR in STAD cell lines confirmed that ANKRD53 was downregulated in STAD samples compared to normal samples in the online databases. As an independent predictive biomarker, ANKRD53 was combined with other clinicopathological parameters to create a prognostic nomogram. Using GSEA, ANKRD53 was found to be involved in five pathways, including the TGF-β signaling pathway. Further investigation revealed that ANKRD53 was associated with immune checkpoint molecules, immunological pathways, and immunotherapy, in addition to MSI, TMB and neoantigens. In addition, scRNA-seq data revealed that ANKRD53 is mainly expressed in CD8+ T and dendritic cells. Conclusions ANKRD53 is an important biomarker for STAD that deserves further attention.
- Published
- 2024
- Full Text
- View/download PDF
3. Prognostic role of pretreatment 18F-FDG PET/CT and hematological parameters in relapsed/refractory Hodgkin lymphoma patients treated with immune checkpoint inhibitors and chemotherapy: a dual-center cohort study
- Author
-
Yang, Tianyu, Liu, Shuang, Zuo, Rui, Liang, Hongwei, Xu, Lu, Wang, Zhengjie, Chen, Xiaoliang, and Pang, Hua
- Published
- 2023
- Full Text
- View/download PDF
4. Clinicopathological features and prognosis of patients with HER2-low breast cancer
- Author
-
Xin Yang, Yao Li, Xu lu, Xiaotian Ren, and Bin Hua
- Subjects
Breast cancer ,HER2-low expression ,Clinicopathological features ,Prognosis ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Low human epidermal growth factor receptor 2 (HER2) expression is an emerging concept in breast cancer that is defined as immunohistochemistry (IHC) 1 + or IHC 2 + and negative in situ hybridization (ISH) but has been poorly investigated. The aim of our study was to determine the frequency of low HER2 expression among HER2-negative breast cancers and compare the clinicopathological features and prognosis of HER2-low patients with those of HER2-zero patients. Methods We collected the data of 684 patients with primary HER2-negative breast cancer who underwent surgery between January 2012 and September 2021 from our self-built database. Clinicopathological features, recurrence-free interval (RFI) and breast cancer-specific survival (BCSS) were compared between HER2-low and HER2-zero (IHC 0) patients. Results Among the 684 patients, 512 (74.9%) patients had low HER2 expression, and 172 (25.1%) patients had zero HER2 expression. The average age was 57.7 ± 12.6 years, 472 (69.0%) patients were aged
- Published
- 2023
- Full Text
- View/download PDF
5. Development and Validation of a Prognosis-Prediction Signature for Patients with Lung Adenocarcinoma Based on 11 Telomere-Related Genes
- Author
-
Jia Liu, Sha Sha, Jian Wang, Xiaowei Gu, Menghua Du, and Xu Lu
- Subjects
telomere ,prognosis ,signature ,lung adenocarcinoma ,tcga ,geo ,Biochemistry ,QD415-436 ,Biology (General) ,QH301-705.5 - Abstract
Background: The occurrence and progression of lung cancer are correlated with telomeres and telomerase. Telomere length is reduced in the majority of tumors, including lung cancers. Telomere length variations have been associated with lung cancer risk and may serve as therapeutic targets as well as predictive biomarkers for lung cancer. Nevertheless, the effects of telomere-associated genes on lung cancer prognosis have not been thoroughly studied. We aim to investigate the relationship between telomere-associated genes and lung cancer prognosis. Methods: The Cancer Genome Atlas and Genotype-Tissue Expression databases were used as training sets to build a predictive model. Three integrated Gene Expression Omnibus datasets served as validation sets. Using cluster consistency analysis and regression with the least absolute shrinkage and selection operator, we developed a telomere-related gene risk signature (TMGsig) based on 11 overall survival-related genes (RBBP8, PLK1, DSG2, HOXA7, ANAPC4, CSNK1E, SYAP1, ALDOA, PHF1, MUTYH, and PGS1). Results: The results indicated a negative outcome for the high-risk score group. Immunological microenvironment and somatic mutations differed between the high- and low-risk groups. A statistically significant difference existed between the low-risk and high-risk groups in terms of the expression levels of B cells and CD4 cells, and the risk score was essentially inversely linked with immune cell expression. Conclusions: TMGsig can predict outcomes in patients with lung adenocarcinoma.
- Published
- 2023
- Full Text
- View/download PDF
6. Prognostic value and outcome for acute lymphocytic leukemia in children with MLL rearrangement: a case-control study
- Author
-
Qiu, Kun-yin, Zhou, Dun-hua, Liao, Xiong-yu, Huang, Ke, Li, Yang, Xu, Hong-gui, Weng, Wen-jun, Xu, Lu-hong, and Fang, Jian-pei
- Published
- 2022
- Full Text
- View/download PDF
7. Effects of single-port and two-port video-assisted thoracic day surgery on postoperative pain and early prognosis in patients with pulmonary nodules.
- Author
-
SUN Hang, WANG Min, NIU Shujie, ZHONG Yiwei, LU Ziyun, XU Lu, YANG Rusong, WANG Tao, SUN Yu'e, MA Zhengliang, and LI Bingbing
- Subjects
VIDEO-assisted thoracic surgery ,AMBULATORY surgery ,PULMONARY nodules ,POSTOPERATIVE pain ,PROGNOSIS ,CHEST endoscopic surgery - Abstract
Objectives The research aimed to determine the effects of different surgical procedures on postsurgical pain and early prognosis. We reviewed the perioperative data of patients who underwent single/two-port television-assisted thoracoscopic pulmonary nodule surgery in the day surgery ward of Nanjing Drum Tower Hospital. Methods The clinical and follow-up data of 693 patients undergoing thoracoscopic for pulmonary nodules in the day surgery ward under the centralized management model of our hospital were retrospectively analyzed during the period of January 2021 to December 2022. The patients were divided into a single-port and a two-port thoracoscopy group. The propensity-matching was used to balance the baseline data and analyze the differences in postoperative pain and prognosis of the patientsin the two groups. Results After propensity score matching, the single-port group had lower intraoperative fentanyl consumption [0.5 (0.35, 0.50) mg vs. 0.5 (0.40, 0.50) mg, P = 0.034], remifentanil consumption [0.48 (0.33, 0.63) mg vs. 0.53 (0.35, 0.73) mg, P = 0.031], intraoperative hemorrhage [20 (10, 50) mL vs. 50 (20, 50) mL, P = 0.001], and Visual Analogue Scale on postoperative third day [2 (2, 4) point vs. 3 (2, 4) point, P = 0.007], which were statistically different. There were no statistically significant differences between the two groups in terms of postoperative rescue analgesia, chest drainage volume, length of hospitalization, pain on postoperative 1st, 5th, 9th, and 30th days, postoperative cough, pulmonary complications within 30 days after surgery, and unplanned hospital visits. Conclusion Compared with two-port thoracoscopy, single-port thoracoscopic day surgery for pulmonary nodules is a safe and feasible procedure that can significantly reduce the use of intraoperative opioid analgesics and the pain level of patients on postoperative 3rd day. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Correlation analysis of serum thyroid stimulating hormone with acute cerebrovascular disease
- Author
-
Zhu, Jian, Chen, Ming, Li, Nan, Yang, Shaoling, Xu, Lu, Wang, Yanru, and Li, Hong
- Published
- 2019
- Full Text
- View/download PDF
9. Serum hsa_circ_0087776 as a new oncologic marker for the joint diagnosis of multiple myeloma
- Author
-
Xingxing Gong, Xu Lu, Jing Cao, Huan Liu, Hongmei Chen, Fang Bao, Xiuying Shi, and Hui Cong
- Subjects
Male ,diagnosis ,Bioengineering ,RNA, Circular ,General Medicine ,Prognosis ,Applied Microbiology and Biotechnology ,hsa_circ_0087776 ,Cell Line ,Gene Expression Regulation, Neoplastic ,MicroRNAs ,ROC Curve ,Multiple myeloma ,Cell Line, Tumor ,Biomarkers, Tumor ,Humans ,biomarker ,Female ,quantitative real-time PCR ,serum ,TP248.13-248.65 ,Aged ,Research Article ,Research Paper ,Biotechnology - Abstract
Multiple myeloma (MM) is a hematologic malignancy caused by abnormal proliferation of bone marrow plasma cells, which lacks diagnostic markers and has a general prognosis. At present, the understanding of its pathogenesis provides the basis for the combined diagnosis and new targeted therapy of the disease. In this study, quantitative real-time PCR was used to detect 136 MM patients and 74 healthy controls, and the clinical application value of hsa_circ_0087776 as a new tumor marker and combined diagnosis was evaluated. The results showed that the expression of hsa_circ_0087776 was significantly lower in serum of MM patients (P-value < 0.0001), and the expression was consistent in MM cells. In the analysis of clinicopathological parameters, it was found that there were significant statistical differences with MM stage and renal injury. In addition, it significantly increased the sensitivity with ALB, β₂-MG joint diagnosis, to provide a basis for diagnosis, improve the prognosis of the disease, improve the survival of patients and quality of life. These studies suggest that hsa_circ_0087776 can be used as a new oncology marker for the combined diagnosis of MM. Impact statement: Various evidences have shown that the role of circRNA in the occurrence and development of diseases is potentially unknown and untapped. Therefore, it has a broad prospect to find circRNA specifically expressed in MM patients for combined diagnosis and targeted therapy of MM. However, MM lacks such specific tumor markers. Therefore, the discovery of new specific tumor markers for combined diagnosis is an important milestone in the development of medical history. In the research, we founded hsa_circ_0087776 can be used as a new oncology marker for combined diagnosis of MM.
- Published
- 2021
10. Prognostic Role and Potential Mechanisms of the Ferroptosis-Related Metabolic Gene Signature in Hepatocellular Carcinoma
- Author
-
Linsen Ye, Lele Zhang, Jing Li, Yang Yang, Tianxing Dai, Haoyuan Yu, Mingbin Deng, Shuguang Zhu, Guoying Wang, Wei Liu, and Xu Lu
- Subjects
Pharmacology ,Oncology ,medicine.medical_specialty ,Framingham Risk Score ,Proportional hazards model ,business.industry ,Cancer ,hepatocellular carcinoma ,Gene signature ,Nomogram ,medicine.disease ,gene signature ,ferroptosis ,Immune checkpoint ,Transcriptome ,Pharmacogenomics and Personalized Medicine ,Internal medicine ,Hepatocellular carcinoma ,medicine ,Molecular Medicine ,prognosis ,business ,metabolism ,Original Research - Abstract
Tianxing Dai,1,* Jing Li,2,* Xu Lu,3,* Linsen Ye,1 Haoyuan Yu,1 Lele Zhang,1 Mingbin Deng,1 Shuguang Zhu,1 Wei Liu,3 Guoying Wang,4 Yang Yang1 1Department of Hepatic Surgery and Liver Transplant Program, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Peopleâs Republic of China; 2Department of Infectious Diseases and Hepatology Unit, Nanfang Hospital, Southern Medical University, Guangzhou, Peopleâs Republic of China; 3Guangdong Key Laboratory of Liver Disease Research, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Peopleâs Republic of China; 4Department of Hepatobiliary Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Peopleâs Republic of China*These authors contributed equally to this workCorrespondence: Guoying WangDepartment of Hepatobiliary Surgery, The First Affiliated Hospital of Guangzhou Medical University, 151 Yanjiangxi Road, Guangzhou, 510120, Peopleâs Republic of ChinaTel +86-020-83062703Fax +86-020-83395651Email wanggy3@126.comYang YangDepartment of Hepatic Surgery and Liver Transplant Program, The Third Affiliated Hospital of Sun Yat-Sen University, 600 Tianhe Road, Guangzhou, 510630, Peopleâs Republic of ChinaTel +86-020-85252177Fax +86-020-85252276Email yysysu@163.comPurpose: Ferroptosis, as a novel regulated cell death form, has a close interaction with metabolism, which is largely unknown in cancer. In the present study, we conducted a comprehensive analysis of ferroptosis-related metabolic genes to delineate the metabolic signatures induced by ferroptosis and evaluate its prognostic significance in hepatocellular carcinoma (HCC).Methods: The ferroptosis-related metabolic genes (Fer-MRGs) were identified by correlation analyses with transcriptome data from The Cancer Genome Atlas and Gene Expression Omnibus. Then, univariate and the least absolute shrinkage and selection operator Cox regression analysis was used to establish a novel risk score model. Univariate and multivariate COX analyses were used to identify independent prognostic factors for overall survival (OS) of HCC, and a nomogram was developed. The Fer-MRGsâ expression was further evaluated by quantitative real-time polymerase chain reaction in HCC.Results: A total of 77 metabolic genes were identified as Fer-MRGs, and 26 were found with prognostic values for OS of HCC. Then, a novel nine-gene (AKR1C3, ATIC, G6PD, GMPS, GNPDA1, IMPDH1, PRIM1, RRM2, and TXNRD1) risk score model was constructed. Survival analyses showed worse OS in high-risk patients both in the training and validation groups. The model was also identified as an independent prognostic factor for HCC, and a prognostic nomogram for OS was further established with superior discriminative capacity and prediction accuracy. Notably, close correlations were also identified between the risk score and the expression of immune checkpoint genes, immune subtypes of tumor, and susceptibility of HCC to chemotherapeutic agents. Finally, elevated expression of eight Fer-MRGs (except for IMPDH1) was further verified in 16 pairs of HCC tumor and adjacent tissues.Conclusion: These results indicated the intense interaction between ferroptosis and metabolism, the significant role of ferroptosis-related MRGs, and the great potential of the novel risk score model for prognosis prediction in HCC.Keywords: hepatocellular carcinoma, ferroptosis, metabolism, gene signature, prognosis
- Published
- 2021
11. PROZ Associated with Sorafenib Sensitivity May Serve as a Potential Target to Enhance the Efficacy of Combined Immunotherapy for Hepatocellular Carcinoma
- Author
-
Yinkui Chen, Xiusheng Qiu, Donghao Wu, Xu Lu, Guanghui Li, Yongsheng Tang, Changchang Jia, Zhiyong Xiong, and Tiantian Wang
- Subjects
PROZ ,KDR ,sorafenib ,immunotherapy ,hepatocellular carcinoma ,Carcinoma, Hepatocellular ,Liver Neoplasms ,Genetics ,Humans ,Immunotherapy ,Sorafenib ,Prognosis ,Genetics (clinical) - Abstract
Targeted combined immunotherapy has significantly improved the prognosis of patients with advanced hepatocellular carcinoma and has now become the primary treatment for advanced hepatocellular carcinoma. However, some patients still have poor efficacy or are resistant to treatment. The further exploration of molecular markers related to efficacy or finding molecular targets to increase efficacy is an urgent problem that needs to be resolved. In this research, we found that PROZ was a gene related to KDR expression that had significantly low expression in cancer tissue by analyzing the differential genes of cancer tissue and adjacent tissue and the intersection of KDR-related genes in hepatocellular carcinoma. The correlation analysis of clinical data showed that the low expression of PROZ was significantly correlated with the poor prognosis of hepatocellular carcinoma, and further studies found that PROZ was closely related to the expression of p-ERK and VEGFR2 in hepatocellular carcinoma. In addition, intracellular detection also showed that the expression of p-ERK increased and VEGFR2 expression decreased after PROZ interference, and PROZ downregulation with increased p-ERK and decreased VEGFR2 was also detected in sorafenib-resistant strains. At the same time, our analysis found that PROZ was negatively correlated with genes related to immunotherapy efficacy such as CD8A, CD274 and GZMA, and was also negatively correlated with T-cell infiltration in tumor tissue. Conclusion: PROZ is a gene related to the prognosis of hepatocellular carcinoma and it is closely related to the efficacy of sorafenib and immunotherapy. It may serve as a potential molecular target to improve the efficacy of targeted combined immunotherapy.
- Published
- 2022
- Full Text
- View/download PDF
12. MicroRNA-29b-2-5p inhibits cell proliferation by directly targeting Cbl-b in pancreatic ductal adenocarcinoma
- Author
-
Li, Ce, Dong, Qian, Che, Xiaofang, Xu, Ling, Li, Zhi, Fan, Yibo, Hou, Kezuo, Wang, Shuo, Qu, Jinglei, Xu, Lu, Wen, Ti, Yang, Xianghong, Qu, Xiujuan, and Liu, Yunpeng
- Published
- 2018
- Full Text
- View/download PDF
13. MicroRNA expression profiles in muscle-invasive bladder cancer: identification of a four-microRNA signature associated with patient survival
- Author
-
Xu, Zheng, Yu, Yan-Qiu, Ge, Yu-Zheng, Zhu, Jia-Geng, Zhu, Meng, Zhao, You-Cai, Xu, Lu-Wei, Yang, Xiao-Bing, Geng, Li-Guo, Dou, Quan-Liang, and Jia, Rui-Peng
- Published
- 2015
- Full Text
- View/download PDF
14. Diagnostic and prognostic values of AKR1C3 and AKR1D1 in hepatocellular carcinoma
- Author
-
Pengfei Zhu, Wenlong Zhai, Yuan Liao, Ruo Feng, Zhicheng Du, Xu Lu, and Kunlun Chen
- Subjects
Male ,MAPK/ERK pathway ,Aging ,Carcinoma, Hepatocellular ,diagnosis ,Down-Regulation ,Reductase ,medicine.disease_cause ,Cell Line, Tumor ,Humans ,Medicine ,Protein Interaction Maps ,RNA, Messenger ,KEGG ,Cell Proliferation ,Proportional Hazards Models ,Gene knockdown ,business.industry ,Cell growth ,Liver Neoplasms ,Aldo-Keto Reductase Family 1 Member C3 ,hepatocellular carcinoma ,Hep G2 Cells ,Cell Biology ,AKR1C3 ,Middle Aged ,Prognosis ,medicine.disease ,Up-Regulation ,Survival Rate ,Androgen receptor ,Gene Ontology ,ROC Curve ,Area Under Curve ,Case-Control Studies ,Gene Knockdown Techniques ,Hepatocellular carcinoma ,AKR1D1 ,Cancer research ,Female ,Oxidoreductases ,business ,Carcinogenesis ,Research Paper - Abstract
Hepatocellular carcinoma (HCC) is the most common histological type of primary liver cancer and the majority of patients are diagnosed at an advanced stage and have a poor prognosis. AKR1C3 (Aldo-keto reductase family 1 member C3) and AKR1D1 (Aldo-keto reductase family 1 member D1) catalyze the conversion of aldehydes and ketones to alcohols and play crucial roles in multiple cancers. However, the functions of AKR1C3 and AKR1D1 in HCC remain unclear. In our study, data from the public databases were selected as training and validation sets, then 76 HCC patients in our center were chosen as a test set. Bioinformatics methods suggested AKR1C3 was overexpressed in HCC and AKR1D1 was down-regulated. The receiver operating characteristic curve (ROC) analysis was performed and the area under curve (AUC) values of AKR1C3 and AKR1D1 were above 0.7 (0.948, 0.836, respectively). Also, the high expression of AKR1C3 and low expression of AKR1D1 predicted poor prognosis and short median survival time. Then, the knockdown of AKR1C3 and overexpression of AKR1D1 in HCC cells were achieved with lentivirus. And both decreased cell proliferation, restrained cell viability, and inhibited tumorigenesis. Moreover, the gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were conducted and the results showed that AKR1C3 and AKR1D1 might participate in the MAPK/ERK and androgen receptor (AR) signaling pathway. Furthermore, the AR and phosphorylated ERK1/2 were significantly reduced after the suppression of AKR1C3 or overexpression of AKR1D1. Collectively, AKR1C3 and AKR1D1 might serve as candidate diagnostic and prognostic biomarkers for HCC and provide potential targets for HCC treatment.
- Published
- 2021
15. Relationship between marital status and survival in patients with lung adenocarcinoma
- Author
-
Wu, Ying, Zhu, Pei-Zhen, Chen, Yin-Qiao, Chen, Jie, Xu, Lu, and Zhang, Huayi
- Subjects
Adult ,Male ,Lung Neoplasms ,Observational Study ,Adenocarcinoma of Lung ,Kaplan-Meier Estimate ,survival analysis ,Young Adult ,cancer-specific survival ,Risk Factors ,Carcinoma, Non-Small-Cell Lung ,SEER program ,Humans ,Aged ,Aged, 80 and over ,Marital Status ,Middle Aged ,lung adenocarcinoma ,Prognosis ,Survival Analysis ,Survival Rate ,Female ,Research Article ,marital status ,SEER Program - Abstract
Numerous studies have focused on whether the marital status has an impact on the prognosis in patients with non-small cell lung cancer, but none have focused on lung adenocarcinoma. We selected 61,928 eligible cases with lung adenocarcinoma from the Surveillance, Epidemiology, and End Results database from 2004 to 2016 and analyzed the impact of marital status on cancer-specific survival (CSS) using Kaplan–Meier and Cox regression analyses. We confirmed that sex, age, race, cancer TNM stage and grade, therapeutic schedule, household income, and marital status were independent prognostic factors for lung adenocarcinoma CSS. Multivariate Cox regression showed that widowed patients had worse CSS (hazard ratio 1.26, 95% confidence interval 1.20–1.31, P
- Published
- 2022
16. Prognostic role of pretreatment 18F-FDG PET/CT and hematological parameters in relapsed/refractory Hodgkin lymphoma patients treated with immune checkpoint inhibitors and chemotherapy: a dual-center cohort study.
- Author
-
Yang, Tianyu, Liu, Shuang, Zuo, Rui, Liang, Hongwei, Xu, Lu, Wang, Zhengjie, Chen, Xiaoliang, and Pang, Hua
- Subjects
IMMUNE checkpoint inhibitors ,POSITRON emission tomography ,HODGKIN'S disease ,RECEIVER operating characteristic curves ,CANCER chemotherapy ,LACTATE dehydrogenase ,PROGRAMMED cell death 1 receptors ,POLYETHYLENE terephthalate - Abstract
Background: The combination of anti-programmed death-1 antibodies and chemotherapy is effective; however, there are no reliable outcome prediction factors. We investigated the prognostic factors based on
18 Fluorine-fluorodeoxyglucose positron emission tomography/computed tomography (18 F-FDG PET/CT) quantitative and hematological parameters to predict progression-free survival (PFS) in relapsed/refractory classical Hodgkin lymphoma (R/R cHL) patients treated with immune checkpoint inhibitors (ICIs) and chemotherapy. Methods: This retrospective study included 31 patients who underwent18 F-FDG PET/CT before and during treatment. Pretreatment metabolic and hematological parameters were evaluated using Cox regression analysis to identify predictors of PFS. Based on the cut-off values calculated using the receiver operating characteristic (ROC) curve, patients were classified into low-, intermediate-, and high-risk groups. Kaplan–Meier curves and the log-rank test were used to compare survival differences between the groups. Results: Cox multivariable analysis indicted that the treatment response based on Lactate dehydrogenase (LDH), Lugano classification and SUVmax were independent predictors of PFS (P = 0.004, 0.007 and 0.039, respectively). The optimal cut-off values for SUVmax and LDH were 11.62 and 258.5 U/L, respectively (P < 0.01). Survival curves showed that LDH ≥ 258.5U/L and SUVmax ≥ 11.62 were correlated to shorter PFS (P < 0.001, P = 0.003, respectively). The differences in PFS between the low-, intermediate-, and high-risk groups were statistically significant (P = 0.0043). Conclusion: In R/R cHL patients treated with ICIs and chemotherapy, Lugano classification, SUVmax , and LDH were significantly correlated with PFS. The combination of metabolic and hematological parameters predicts PFS and may help to improve patient selection. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
17. Mutational landscape and clinical outcome of pediatric acute myeloid leukemia with 11q23/KMT2A rearrangements.
- Author
-
Yuen, Ka‐Yuk, Liu, Yong, Zhou, Yong‐Zhuo, Wang, Yin, Zhou, Dun‐Hua, Fang, Jian‐Pei, and Xu, Lu‐Hong
- Subjects
ACUTE myeloid leukemia ,TREATMENT effectiveness ,CHILD patients ,NUCLEOTIDE sequencing ,PROGNOSIS - Abstract
Background: Alterations of 11q23/KMT2A are the most prevalent cytogenetic abnormalities in acute myeloid leukemia (AML) and the prognostic significance of 11q23/KMT2A‐rearranged AML based on various translocation partners varies among different studies. However, few studies evaluated the molecular characteristics of 11q23/KMT2A‐rearranged pediatric AML. We aim to analyze the mutational landscape of 11q23/KMT2A‐rearranged AML and assess their prognostic value in outcomes. Methods: The mutational landscape and clinical prognosis of 105 children with 11q23/KMT2A‐rearranged AML in comparison with 277 children with non‐11q23/KMT2A‐rearranged AML were analyzed using publicly accessible next‐generation sequencing data from Therapeutically Applicable Research to Generate Effective Treatments (TARGET) dataset. Results: Pediatric AML patients with 11q23/KMT2A‐rearrangements harbored a low number of mutations (Median, 1 mutation/patient, range, 1‐22), 58% of which involved in RAS pathway mutations (KRAS, NRAS, and PTPN11) and 10.5% of which comprised of SETD2 mutations. Compared with non‐11q23/KMT2A‐rearranged AML, the incidence of KRAS (32.4% vs. 10.1%, P〈0.001) and SETD2 (10.5% vs. 1.4%, P=0.001) gene mutations in 11q23/KMT2A‐rearranged AML was significantly higher. Both KRAS and SETD2 mutations occurred more often in t(10;11)(p12;q23). KRAS mutations were correlated with worse 5‐year event‐free survival [EFS] (Plog‐rank = 0.001) and 5‐year overall survival [OS] (Plog‐rank = 0.009) and the presence of SETD2 mutations increases the 5‐year relapse rate (PGray = 0.004). Multivariate analyses confirmed KRAS mutations in 11q23/KMT2A‐rearranged AML as an independent predictor for poor EFS (hazard ratio [HR] = 2.10, P=0.05) and OS (HR = 2.39, P=0.054). Conclusion: Our findings show that pediatric patients with 11q23/KMT2A rearrangements have characteristic mutation patterns and varying clinical outcomes depending on different translocation partners, which could be utilized to develop more accurate risk stratification and tailored therapies. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
18. Prognostic value of microRNA-10b overexpression in peripheral blood mononuclear cells of nonsmall-cell lung cancer patients
- Author
-
Yang, Yun-Long, Xu, Lu-Ping, Zhuo, Feng-Lin, and Wang, Tian-You
- Published
- 2015
- Full Text
- View/download PDF
19. A tumor-specific microRNA signature predicts survival in clear cell renal cell carcinoma
- Author
-
Ge, Yu-Zheng, Wu, Ran, Xin, Hui, Zhu, Meng, Lu, Tian-Ze, Liu, Hao, Xu, Zheng, Yu, Peng, Zhao, You-Cai, Li, Ming-Hao, Hu, Zhi-Kai, Zhao, Yan, Zhong, Bing, Xu, Xiao, Zhou, Liu-Hua, Xu, Lu-Wei, Wu, Jian-Ping, Li, Wen-Cheng, Zhu, Jia-Geng, and Jia, Rui-Peng
- Published
- 2015
- Full Text
- View/download PDF
20. Serum level of long noncoding RNA B3GALT5-AS1 as a diagnostic biomarker of colorectal cancer
- Author
-
Jian-Kang Ge, Ting-Ting Liu, Wei Feng, Lu Dai, Shaoqing Ju, Ye Ding, Juan Yu, Xin-Yi Hua, and Xu Lu
- Subjects
Male ,0301 basic medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,Colorectal cancer ,03 medical and health sciences ,0302 clinical medicine ,Cell Movement ,Internal medicine ,Biomarkers, Tumor ,medicine ,Humans ,Diagnostic biomarker ,Stage (cooking) ,Tumor node metastasis ,Cell Proliferation ,business.industry ,Cancer ,Diagnostic marker ,General Medicine ,Middle Aged ,Galactosyltransferases ,Prognosis ,medicine.disease ,Long non-coding RNA ,Gene Expression Regulation, Neoplastic ,030104 developmental biology ,030220 oncology & carcinogenesis ,Colonic Neoplasms ,Biomarker (medicine) ,Female ,RNA, Long Noncoding ,Colorectal Neoplasms ,business - Abstract
Aim: Long noncoding RNA (lncRNA) B3GALT5-AS1 has been reported as a biomarker for cancer monitoring. This research aims to identify serum long noncoding RNA B3GALT5-AS1 as a new biomarker for the diagnosis of colorectal cancer (CRC) and evaluate its clinical value. Materials & methods: Serum B3GALT5-AS1 expression levels were measured by quantitative real-time PCR. Results: The level of B3GALT5-AS1 in CRC patients was significantly lower than that of healthy patients (p < 0.0001). Further exploration validated that high serum B3GALT5-AS1 level was related to tumor node metastasis (TNM) stage (p = 0.008) and histological differentiation (p = 0.027). Compared with the healthy control group, AUCROC of serum B3GALT5-AS1 in the CRC group was 0.762 with 95% CI: 0.698–0.826 (p < 0.0001). Conclusion: B3GALT5-AS1 may be served as a diagnostic marker for distinguishing CRC patients from healthy people.
- Published
- 2020
21. Optimal time-points for detecting expression levels of BAALC, EVI1, and WT1 genes in patients with acute myeloid leukemia: a meta-analysis
- Author
-
Yuen, Ka-Yuk, Lin, Xiao-Ying, Zhou, Yong-Zhuo, Luo, Hua, Liu, Yong, and Xu, Lu-Hong
- Subjects
Leukemia, Myeloid, Acute ,Gene Expression Regulation, Leukemic ,Humans ,Antineoplastic Agents ,Hematology ,Prognosis ,WT1 Proteins ,MDS1 and EVI1 Complex Locus Protein ,Neoplasm Proteins ,Up-Regulation - Abstract
This meta-analysis examined the prognostic role of brain and acute leukemia, cytoplasmic (BAALC), Ecotropic virus integration site-1 (EVI1) and Wilms’ tumor 1 (WT1) genes at different time-points during conventional chemotherapy. A systematic search of publications indexed in the electronic databases from January 1988 to October 2020 was performed. Over 7525 cases of AML from 25 studies were involved. At diagnosis, overexpression of either BAALC or EVI1 had a negative impact on complete remission achievement (Summary Odds ratios [SORs] for BAALC = 0.32; SORs for EVI1 = 0.49) and survival outcome. The summary hazard ratios of overall survival (OS) and disease-free survival (DFS) were 1.97 and 2.04 for BAALC and 1.33 and 1.86 for EVI1, respectively. The prognostic value of pretreatment WT1 levels was heterogeneous while subgroup analyses unveiled that overexpressed WT1 may correlate with a favorable outcome (summary hazard ratio [SHR] for OS = 0.42). Both WT1 and BAALC played a role in prognosis assessment at post-induction and the diagnostic performance of WT1 transcript reduction was superior to the absolute WT1 level. Post-consolidation WT1 overexpression consistently indicated an increased risk of relapse, while the combined HR for RFS was statistically insignificant (SHR = 4.22). These findings confirm the application of BAALC and EVI1 at diagnosis, WT1 after induction chemotherapy in AML patients throughout conventional chemotherapy.
- Published
- 2021
22. Regulation Network and Prognostic Significance of Aldo-Keto Reductase (AKR) Superfamily Genes in Hepatocellular Carcinoma
- Author
-
Yang Yang, Xu Lu, Rongqiang Liu, Jing Li, Guoying Wang, Wei Liu, Kun Li, Linsen Ye, Mingbin Deng, Haoyuan Yu, Tianxing Dai, and Rong Li
- Subjects
hepatocellular carcinoma ,Biology ,medicine.disease ,digestive system diseases ,risk score model ,law.invention ,Transcriptome ,nomogram ,aldo-keto reductase ,Germline mutation ,law ,Hepatocellular carcinoma ,DNA methylation ,medicine ,Cancer research ,Immunohistochemistry ,prognosis ,AKR ,Gene ,Transcription factor ,Polymerase chain reaction ,Journal of Hepatocellular Carcinoma ,Original Research - Abstract
Purpose The aldo-keto reductase (AKR) superfamily members have been proposed with multiple roles in various tumors. Here, a comprehensive analysis on the integral role of AKR genes was conducted to evaluate the expression profile, regulation network, and prognostic significance in hepatocellular carcinoma (HCC). Materials and Methods Transcriptome datasets of HCC were obtained from the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus. Univariate and multivariate Cox regression analyses were used to build a novel risk score model, and then were further used to identify independent prognostic factors for overall survival (OS) of HCC. A prognostic nomogram was developed and validated. The expression of these critical AKR members was also evaluated by quantitative real-time polymerase chain reaction and immunohistochemistry in HCC specimens. Results Eight differentially expressed AKR genes were identified in HCC. The dysregulation of most AKR genes was negatively correlated with DNA methylation, and a regulation network with transcription factors (TFs) was also established. Then, three critical AKR genes (AKR1B10, AKR1D1, and AKR7A3) were screened out to build a novel risk score model. Worse OS was observed in high-risk patients. Besides, a prognostic nomogram based on the model was further established and validated in both the TCGA and GSE14520 cohorts, which showed superior performance in predicting the OS of HCC patients. Notably, close correlations were identified between the risk score and tumor immune microenvironment, somatic mutation profiles, and drug susceptibilities of HCC. Finally, the upregulated AKR1B10 and downregulated AKR1D1 and AKR7A3 were further verified in HCC tumor and adjacent tissues from our institution. Conclusion The dysregulated AKR genes could be mediated by DNA methylation and TFs in HCC. The risk model established with superior prognostic performance further suggested the significant role of AKR genes involved in the progression of HCC., Graphical Abstract
- Published
- 2021
23. A comparison between pylorus-preserving and distal gastrectomy in surgical safety and functional benefit with gastric cancer: a systematic review and meta-analysis
- Author
-
Hua Zhu, Wang Baolin, Mao Xinyu, Chunpeng Ji, Xu Lu, and Xu Xinlei
- Subjects
medicine.medical_specialty ,medicine.medical_treatment ,lcsh:Surgery ,Anastomosis ,lcsh:RC254-282 ,Gastroenterology ,law.invention ,Bile reflux ,Pylorus-preserving gastrectomy ,Randomized controlled trial ,law ,Surgical oncology ,Gastrectomy ,Stomach Neoplasms ,Internal medicine ,medicine ,Humans ,Pylorus ,Early gastric cancer ,Gastric emptying ,business.industry ,Research ,lcsh:RD1-811 ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,medicine.disease ,Prognosis ,Early Gastric Cancer ,Meta-analysis ,Treatment Outcome ,Oncology ,Distal gastrectomy ,Strictly standardized mean difference ,Surgery ,sense organs ,Neoplasm Recurrence, Local ,business - Abstract
Background Due to better functional outcomes, pylorus-preserving gastrectomy (PPG) has been widely applied for early gastric cancer (EGC) patients as an alternative to distal gastrectomy (DG). However, controversies still persist regarding the surgical efficacy and oncological safety of PPG. Methods Original studies comparing PPG and DG for EGC were searched in PubMed, Embase, and the Cochrane Register of Controlled Trials up to December 2019. The weight mean difference, standardized mean difference, or odds risk was used to calculate the short-term and long-term outcomes between the two groups. Results Twenty-one comparative studies comprising 4871 patients (1955 in the PPG group and 2916 in the DG group) were enrolled in this systematic review and meta-analysis. PPG showed longer hospital day, decreased harvested lymph nodes, and more delayed gastric emptying. However, PPG had the benefits of lower incidence of anastomosis leakage, early dumping syndrome, gastritis and bile reflux, and better recovery of total protein, albumin, hemoglobin, and weight. No difference was found in operative time, blood loss, and overall complications. Moreover, the long-term survival and recurrence rate were similar in two groups. Conclusion Owing to the non-inferiority of surgery and oncology outcomes and the superiority of function outcomes in PPG, we revealed that PPG can be clinically applicable instead of DG in EGC. However, more high-quality comparative studies and randomized clinical trials would be required for further confirmation.
- Published
- 2020
24. Construction and validation of a prognostic nomogram for anal squamous cell carcinoma.
- Author
-
Yang, Ningning, Xu, Lu, Wang, Qingqing, Chen, Fengxia, and Zhou, Yunfeng
- Subjects
- *
SQUAMOUS cell carcinoma , *NOMOGRAPHY (Mathematics) , *RECEIVER operating characteristic curves , *ANAL cancer , *DECISION making - Abstract
Background: Anal squamous cell carcinoma (ASCC) is the main subtype of anal cancer and has great heterogeneity in prognosis. We aimed to construct a nomogram for predicting their 1‐, 3‐, and 5‐year overall survival (OS) rates. Methods: Patients with ASCC, enrolled between January 1, 2010 and December 31, 2017, were identified from the SEER database. They were divided into a training group and a validation group in a ratio of 7:3. Univariate and multivariate Cox analyses were used to identify the prognostic factors for OS. Then a prognostic nomogram was established and validated by Harrell consistency index (C‐index), area under the curve (AUC) of the receiver operating characteristic (ROC) curves, calibration plots, and decision curve analysis (DCA). Results: We identified 761 patients in training group and 326 patients in validation group. Four prognostic factors including age, sex, AJCC stage, and radiotherapy were identified and integrated to construct a prognostic nomogram. The C‐index and AUC values proved the model's effectiveness and calibration plots manifested its excellent discrimination. Furthermore, in comparison to the AJCC stage, the C‐index, AUC, and DCA proved the nomogram to be of good predictive value. Finally, we constructed a risk stratification model for dividing patients into low‐risk, medium‐risk, and high‐risk groups, and there were obvious differences in OS. Conclusions: A prognostic nomogram was firstly established for predicting the survival probability of ASCC patients and helping clinicians improve their risk management. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
25. DNA index as prognostic factor in childhood acute lymphoblastic leukemia in the COG-TARGET database.
- Author
-
Qiu, Kun-yin, Liao, Xiong-yu, He, Zhan-wen, Wu, Ruo-hao, Li, Yang, Xu, Lu-hong, Zhou, Dun-hua, and Fang, Jian-pei
- Subjects
PROGNOSIS ,LYMPHOBLASTIC leukemia ,ACUTE leukemia ,CHILD patients ,GENE fusion ,DATABASES ,RETROSPECTIVE studies - Abstract
Background: This study was aimed to evaluate the value of DNA index(DI) among pediatric acute lymphoblastic leukemia (ALL) treated on Children's Oncology Group (COG) protocols between 2000 and 2015.Methods: Retrospective study were analysis among pediatric ALL patients from the TARGET dataset.Result: Totally, 1668 eligible pediatric patients were enrolled in this study. Of them, 993 are male and 675 are female with a median age of 7.6 years old. The median follow-up for those patients was 7.7 years (range 0.1-15.7 years). The probability of 15-year EFS and OS were reported to be 67.5 ± 3.1% and 78.3 ± 2.5%, respectively. BCR/ABL1 fusion gene affected the early treatment response and the survival of childhood ALL. Moreover, those patients with ETV6/RUNX1 fusion gene were also significantly associated with better EFS (HR = 0.6, 95% CI 0.4-0.8, P = 0.003) and OS (HR = 0.3, 95%CI 0.2-0.5, P < 0.001) compared to patients with no ETV6/RUNX1. On the contrary, BM NR on Day+ 29 showed a significant decrease in EFS (HR = 3.1, 95%CI 2.1-4.5, P < 0.001) and OS (HR = 1.7, 95%CI 1.1-2.8, P = 0.026). Multivariate analysis showed that DI was significantly associated with better EFS and OS. The threshold effect of DI on poor outcome was significant after adjusting for potential confounders. The adjusted regression coefficient (Log RR) was 0.7 (95%CI 0.1-3.2, P = 0.597) for DI < 1.1 while 8.8 (95%CI 1.4-56.0, P = 0.021) for DI ≥ 1.2 and 0.0 (95%CI 0.0-0.8, P = 0.041) for 1.1 ≤ DI < 1.2. Generalized additive models revealed that the lowest rates of the adverse outcomes estimated to occur among DI between 1.1 and 1.2.Conclusion: For those childhood ALL treated on COG protocols between 2000 and 2015, ETV6/RUNX1 and BM NR were closely related to the prognosis. Moreover, the DI between 1.1 and 1.2 can serve as a significant cut-point discriminating the risk group, which indicated a favourable prognostic factor. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
26. Critical role for the long non-coding RNA AFAP1-AS1 in the proliferation and metastasis of hepatocellular carcinoma
- Author
-
Zhiwei Liang, Chuang Zhou, Xu Lu, Long-shuan Zhao, Shuijun Zhang, Wenlong Zhai, and Renfeng Li
- Subjects
Male ,0301 basic medicine ,Oncology ,Cancer Research ,Lung Neoplasms ,Proliferation ,Apoptosis ,Metastasis ,Immunoenzyme Techniques ,Mice ,0302 clinical medicine ,Invasion ,Cell Movement ,Tumor Cells, Cultured ,HCC ,Reverse Transcriptase Polymerase Chain Reaction ,Cell migration ,General Medicine ,Middle Aged ,Prognosis ,Long non-coding RNA ,Gene Expression Regulation, Neoplastic ,Lymphatic Metastasis ,030220 oncology & carcinogenesis ,Hepatocellular carcinoma ,Disease Progression ,Female ,RNA, Long Noncoding ,Original Article ,AFAP1-AS1 ,medicine.medical_specialty ,Carcinoma, Hepatocellular ,Blotting, Western ,Mice, Nude ,Biology ,Real-Time Polymerase Chain Reaction ,03 medical and health sciences ,Internal medicine ,Biomarkers, Tumor ,medicine ,Animals ,Humans ,Gene silencing ,Neoplasm Invasiveness ,RNA, Messenger ,Cell Proliferation ,Neoplasm Staging ,Cell growth ,Cancer ,medicine.disease ,Xenograft Model Antitumor Assays ,digestive system diseases ,030104 developmental biology ,Case-Control Studies ,Follow-Up Studies - Abstract
Increasing evidence has indicated that dysregulation of long non-coding RNAs (lncRNAs) can contribute to the progression and metastasis of human cancer, including HCC. Previous studies have shown that the lncRNA AFAP1-AS1 plays a critical role in cancer. However, the roles of AFAP1-AS1 in HCC remain to be determined. In the present study, AFAP1-AS1 was found to be increased in HCC tissues, and high AFAP1-AS1 expression was associated with tumor size, TNM stage, vascular invasion, and poor prognosis. Silencing of AFAP1-AS1 significantly reduced cell proliferation, clonal growth, cell migration, and invasion and increased apoptosis in vitro. Furthermore, AFAP1-AS1 silencing markedly reduced tumor growth in a murine allograft model in vivo. The results suggested that AFAP1-AS1 is important in HCC development and serves as a therapeutic target of HCC.
- Published
- 2016
27. Prognostic Value and Related Regulatory Networks of MRPL15 in Non-Small-Cell Lung Cancer.
- Author
-
Zeng, Yangyang, Shi, Yingying, Xu, Lu, Zeng, Yulan, Cui, Xiao, Wang, Yuan, Yang, Ningning, Zhou, Fuxiang, and Zhou, Yunfeng
- Subjects
NON-small-cell lung carcinoma ,PROGNOSIS ,RIBOSOMAL proteins ,MITOCHONDRIAL proteins ,DNA replication - Abstract
Background: Mitochondrial ribosomal protein L15 (MRPL15), a member of mitochondrial ribosomal proteins whose abnormal expression is related to tumorigenesis. However, the prognostic value and regulatory mechanisms of MRPL15 in non-small-cell lung cancer (NSCLC) remain unclear. Methods: GEPIA, ONCOMINE, Gene Expression Omnibus (GEO), UALCAN, Kaplan–Meier plotter, PrognoScan, LinkedOmics and GeneMANIA database were utilized to explore the expression and prognostic value of MRPL15 in NSCLC. Additionally, immune infiltration patterns were evaluated via ESTIMATE algorithm and TISIDB database. Furthermore, the expression and prognostic value of MRPL15 in lung cancer were validated via immunohistochemistry (IHC) assays. Results: In NSCLC, multiple cohorts including GEPIA, ONCOMINE and 8 GEO series (GSE8569, GSE101929, GSE33532, GSE27262, GSE21933, GSE19804, GSE19188, GSE18842) described that MRPL15 was up-regulated. Moreover, MRPL15 was notably linked to gender, clinical stage, lymph node status and the TP53 mutation status. And patients with high MRPL15 expression showed poor overall survival (OS), progression-free survival (PFS), disease-free survival (DFS) and relapse-free survival (RFS) in NSCLC. Then, functional network analysis suggested that MRPL15 participated in metabolism-related pathways, DNA replication and cell cycle signaling via pathways involving several kinases, miRNAs and transcription factors. Additionally, it was found that MRPL15 expression was negatively related to immune infiltration, including immune scores, stromal scores and several tumor-infiltrating lymphocytes (TILs). Furthermore, IHC results further confirmed the high MRPL15 expression and its prognostic potential in lung cancer. Conclusions: These findings demonstrate that high MRPL15 expression indicates poor prognosis in NSCLC and reveal potential regulatory networks as well as the negative relationship with immune infiltration. Thus, MRPL15 may be an attractive predictor and therapeutic strategy for NSCLC. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
28. Wilms Tumor 1 Mutations Are Independent Poor Prognostic Factors in Pediatric Acute Myeloid Leukemia.
- Author
-
Wang, Yin, Weng, Wen-Jun, Zhou, Dun-Hua, Fang, Jian-Pei, Mishra, Srishti, Chai, Li, and Xu, Lu-Hong
- Subjects
ACUTE myeloid leukemia ,NEPHROBLASTOMA ,PROGNOSIS ,HEMATOPOIETIC stem cell transplantation ,CHILD patients - Abstract
The prognostic impact of Wilms tumor 1 (WT1) mutations remains controversial for patients with acute myeloid leukemia (AML). Here, we aimed to determine the clinical implication of WT1 mutations in a large cohort of pediatric AML. The clinical data of 870 pediatric patients with AML were downloaded from the therapeutically applicable research to generate effective treatment (TARGET) dataset. We analyzed the prevalence, clinical profile, and prognosis of AML patients with WT1 mutations in this cohort. Our results showed that 6.7% of total patients harbored WT1 mutations. These WT1 mutations were closely associated with normal cytogenetics (P <0.001), FMS-like tyrosine kinase 3/internal tandem duplication (FLT3 /ITD) mutations (P <0.001), and low complete remission induction rates (P <0.01). Compared to the patients without WT1 mutations, patients with WT1 mutations had a worse 5-year event-free survival (21.7 ± 5.5% vs 48.9 ± 1.8%, P <0.001) and a worse overall survival (41.4 ± 6.6% vs 64.3 ± 1.7%, P <0.001). Moreover, patients with both WT1 and FLT3 /ITD mutations had a dismal prognosis. Compared to chemotherapy alone, hematopoietic stem cell transplantation tended to improve the prognoses of WT1 -mutated patients. Multivariate analysis demonstrated that WT1 mutations conferred an independent adverse impact on event-free survival (hazard ratio 1.910, P = 0.001) and overall survival (hazard ratio 1.709, P = 0.020). In conclusion, our findings have demonstrated that WT1 mutations are independent poor prognostic factors in pediatric AML. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
29. High Expression of CLEC11A Predicts Favorable Prognosis in Acute Myeloid Leukemia.
- Author
-
Yin, Chengliang, Zhang, Junyan, Guan, Wei, Dou, Liping, Liu, Yuchen, Shen, Ming, Jia, Xiaodong, Xu, Lu, Wu, Rilige, and Li, Yan
- Subjects
ACUTE myeloid leukemia ,HEMATOPOIETIC system ,DNA methylation ,PROGNOSIS ,LOG-rank test - Abstract
Background: Acute myeloid leukemia (AML) is a heterogeneous disease of the hematopoietic system, for which identification of novel molecular markers is potentially important for clinical prognosis and is an urgent need for treatment optimization. Methods: We selected C-type lectin domain family 11, member A (CLEC11A) for study via several public databases, comparing expression among a variety of tumors and normal samples as well as different organs and tissues. To investigated the relationship between CLEC11A expression and clinical characteristics, we derived an AML cohort from The Cancer Genome Atlas (TCGA); we also investigated the Bloodspot and HemaExplorer databases. The Kaplan-Meier method and log-rank test were used to evaluate the associations between CLEC11A mRNA expression, as well as DNA methylation, and overall survival (OS), event-free survival (EFS), and relapse-free survival (RFS). DNA methylation levels of CLEC11A from our own 28 de novo AML patients were assessed and related to chemotherapeutic outcomes. Bioinformatics analysis of CLEC11A was carried out using public databases. Results: Multiple public databases revealed that CLEC11A expression was higher in leukemia. The TCGA data revealed that high CLEC11A expression was linked with favorable prognosis (OS p -value = 2e-04; EFS p -value = 6e-04), which was validated in GSE6891 (OS p -value = 0; EFS p -value = 0; RFS p -value = 2e-03). Methylation of CLEC11A was negatively associated with CLEC11A expression, and high CLEC11A methylation level group was linked to poorer prognosis (OS p -value = 1e-02; EFS p -value = 2e-02). Meanwhile, CLEC11A hypermethylation was associated with poor induction remission rate and dismal survival. Bioinformatic analysis also showed that CLEC11A was an up-regulated gene in leukemogenesis. Conclusion: CLEC11A may be used as a prognostic biomarker, and could do benefit for AML patients by providing precise treatment indications, and its unique gene pattern should aid in further understanding the heterogeneous AML mechanisms. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
30. Prognostic Value and Influence of Receptor Conversion on Treatment Regimen in Metastatic Breast Cancer at the First Time of Recurrence.
- Author
-
Shen, Jiming, Xu, Lu, Shi, Jing, Zhao, Lei, Shi, Sha, Feng, Jing, Han, Xu, Shi, Yu, Wei, Qiaochu, Wang, Dongni, Sun, Mingfang, Mi, Xiaoyi, and Teng, Yue'e
- Subjects
- *
METASTATIC breast cancer , *PROGNOSIS , *EPIDERMAL growth factor receptors , *ESTROGEN receptors , *CANCER relapse - Abstract
Purpose: At the first time of metastatic breast cancer recurrence, conversion of the receptors status may occur between primary lesions and metastatic lesions, including the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Whether the decision of the treatment regimen is based on the primary receptor status or that of metastatic lesions is still unclear. Methods: This study enrolled 411 female patients with a diagnosis of metastatic breast cancer at the first time of recurrence to explore the influence of receptor conversion on prognosis prediction and treatment regimen of patients with metastatic breast cancer. Results: ER and PR changes from negative to positive are both prognostic factors for patients with breast cancer. Patients receiving endocrine therapy showed a better survival after recurrence than those using chemotherapy alone in the ER or PR Prim– Met+ subgroup. Patients in the HER2 Prim– Met+ subgroup using HER2-targeted therapy in multilines showed a post-recurrence survival advantage. In the bone re-biopsy subgroup, the PR change from positive to negative appeared to be more frequent than at other re-biopsy sites. Conclusions: Patients with metastatic breast cancer should perform re-biopsy to clarify the receptor status of the first metastatic lesions, which may provide clinicians valuable evidence to conduct treatments with higher precision. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
31. MicroRNA-26a suppresses angiogenesis in human hepatocellular carcinoma by targeting hepatocyte growth factor-cMet pathway
- Author
-
Hu-Liang Jia, Qiongzhu Dong, Lei Liang, Lun-Xiu Qin, Xu Lu, Xin Yang, Xiao-Fei Zhang, and Qing-Hai Ye
- Subjects
Vascular Endothelial Growth Factor A ,medicine.medical_specialty ,Carcinoma, Hepatocellular ,Angiogenesis ,Biology ,Metastasis ,Neovascularization ,Mice ,Growth factor receptor ,Cell Movement ,Internal medicine ,microRNA ,medicine ,Animals ,Humans ,Gene silencing ,Cell Proliferation ,Mice, Inbred BALB C ,Neovascularization, Pathologic ,Hepatology ,Hepatocyte Growth Factor ,Liver Neoplasms ,Proto-Oncogene Proteins c-met ,Prognosis ,medicine.disease ,digestive system diseases ,MicroRNAs ,Vascular endothelial growth factor A ,Endocrinology ,Cancer research ,Hepatocyte growth factor ,medicine.symptom ,Signal Transduction ,medicine.drug - Abstract
MicroRNA (miR)-26a can suppress tumor growth and metastasis of hepatocellular carcinoma (HCC). Since angiogenesis is important for tumor growth and metastasis, we investigated the possible roles of miR-26a in tumor angiogenesis. Down-regulation of miR-26a was found to correlate with an increased angiogenic potential of HCC. Through gain- and loss-of-function studies, miR-26a was demonstrated to significantly inhibit vascular endothelial growth factor A (VEGFA) expression in HCC cells and then suppress the promoting effects of HCC cells on in vitro proliferation, migration, and capillary tube formation of endothelial cells, as well as in vivo tumor angiogenesis of HCC. Hepatocyte growth factor (HGF) was identified as a target of miR-26a. HGF simulation antagonized the effects induced by miR-26a up-regulation. In contrast, silencing HGF induced similar effects to miR-26a. We further found that miR-26a exerted its antiangiogenesis function, at least in part, by inhibiting HGF-hepatocyte growth factor receptor (cMet) and its downstream signaling pathway, in turn, suppressing VEGFA production in HCC cells and impairing VEGFR2-signaling in endothelial cells. HCC patients who had high miR-26a, low HGF, low VEGFA, or low microvessel density (MVD) in tumor tissues had a better prognosis with longer overall survival (OS) and time to recurrence (TTR). In multivariate analysis, miR-26a, or in combination with HGF, was demonstrated to be an independent prognostic indicator for OS and TTR of HCC patients. Conclusion: miR-26a could suppress tumor angiogenesis of HCC through HGF-cMet signaling, and it is a new hopeful therapeutic target and prognostic marker for HCC. (Hepatology 2014;59:1874–1885)
- Published
- 2014
32. Analysis of Multiple Factors Involved in Pertussis-Like Coughing.
- Author
-
Cao, Jiaying, Xu, Lu, and Pan, Jiahua
- Subjects
- *
BORDETELLA pertussis , *HOSPITAL care of children , *GLUCOCORTICOIDS , *IMMUNIZATION , *MACROLIDE antibiotics , *MEDICAL records , *RISK assessment , *SULFAMETHOXAZOLE , *WHOOPING cough , *LOGISTIC regression analysis , *RETROSPECTIVE studies , *INHALATION administration , *LEUKOCYTE count , *LYMPHOCYTE count , *ACQUISITION of data methodology - Abstract
Objectives. To identify risk factors associated with the prognosis of pertussis-like coughing. Methods. A retrospective study on children hospitalized with pertussis-like coughing from 2018 to 2019. We collected all the case data from medical records including age, gender, vaccination, clinical symptoms, complication, pathogens, white blood cell (WBC) count, lymphocyte ratio, application of macrolide antibiotics, usage of sulfamethoxazole, and usage of inhaled glucocorticoids. Logistic regression was used in this study. Results. A total of 213 hospitalized children with pertussis-like coughing were included in this study. About 70 children were cured within 2 weeks. One120 children were cured from 2 weeks to 3 months, including cases of initial attack and relapse. Symptoms lasting longer than 3 months accounts for 10.8%. Bordetella pertussis, WBC count >20 × 109/L and lymphocyte ratio >60% were associated with poor prognosis (P <.05). Conclusions. Bordetella pertussis, WBC count, and lymphocyte ratio are independent risk factors for poor prognosis. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
33. Cox-LASSO Analysis Reveals a Ten-lncRNA Signature to Predict Outcomes in Patients with High-Grade Serous Ovarian Cancer.
- Author
-
Xu, Lu, Wu, Ying, Che, Xiaofang, Zhao, Jia, Wang, Fang, Wang, Pengshuo, Qu, Xiujuan, Liu, YunPeng, and Li, Zhi
- Subjects
- *
OVARIAN cancer , *SPINDLE apparatus , *NON-coding RNA , *PROGRESSION-free survival , *ADJUVANT treatment of cancer - Abstract
High-grade serous ovarian cancer (HGSOC) is one of the most common and lethal gynecological cancers. Long noncoding RNAs (lncRNAs) play important roles and act as prognostic biomarkers of ovarian cancer. However, few studies have focused on the prognostic prediction of lncRNAs solely in HGSOC. In this study, we identified candidate lncRNAs for a prognostic evaluation by examining reannotated lncRNA expression profiles and clinical data of 343 patients with HGSOC from The Cancer Genome Atlas. We built a 10-lncRNA signature using Cox-LASSO regression to predict the prognosis of patients with HGSOC. Trichotomized by the 10-lncRNA signature, high-risk patients experienced significantly shorter disease-free survival and overall survival (OS). Our novel 10-lncRNA signature showed superior predictive capacity compared to the other 2 published lncRNA signature models and clinicopathological parameters. We developed a nomogram for clinical use by integrating the 10-lncRNA signature and two clinicopathological risk factors to predict 1-, 3-, and 5-year OS. In addition, gene set enrichment analysis suggested that the group of high-risk patients was associated with mitotic spindle pathways. This model was also compatible with patients with or without BRCA1/2 mutations and had the potential to predict the response to platinum-based adjuvant chemotherapy. Our findings provide a novel 10-lncRNA prognostic signature for further clinical application in patients with HGSOC and indicate the underlying mechanisms of HGSOC progression. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
34. Genomewide identification of a novel six‐LncRNA signature to improve prognosis prediction in resectable hepatocellular carcinoma.
- Author
-
Wu, Ying, Wang, Peng‐Shuo, Wang, Ben‐Gang, Xu, Lu, Fang, Wan‐Xia, Che, Xiao‐Fang, Qu, Xiu‐Juan, Liu, Yun‐Peng, and Li, Zhi
- Subjects
NON-coding RNA ,CELL cycle ,LOG-rank test ,LIVER cancer ,POTENTIAL functions - Abstract
The current prognostic long noncoding RNA (lncRNA) signatures for hepatocellular carcinoma (HCC) are still controversial and need to be optimized by systematic bioinformatics analyses with suitable methods and appropriate patients. Therefore, we performed the study to establish a credible lncRNA signature for HCC outcome prediction and explore the related mechanisms. Based on the lncRNA profile and the clinical data of carefully selected HCC patients (n = 164) in TCGA, six of 12727 lncRNAs, MIR22HG, CTC‐297N7.9, CTD‐2139B15.2, RP11‐589N15.2, RP11‐343N15.5, and RP11‐479G22.8 were identified as the independent predictors of patients' overall survival in HCC by sequential univariate Cox and 1000 times Cox LASSO regression with 10‐fold CV, and multivariate Cox analysis with 1000 times bootstrapping. In the Kaplan‐Meier analysis with patients trichotomized by the six‐lncRNA signature, high‐risk patients showed significantly shorter survival than mid‐ and low‐risk patients (log‐rank test P < 0.0001). According to the ROCs, the six‐lncRNA signature showed superior predictive capacity than the two existing four‐lncRNA combinations and the traditional prognostic clinicopathological parameter TNM stage. Furthermore, low MIR22HG and CTC‐297N7.9, but high CTD‐2139B15.2, RP11‐589N15.2, RP11‐343N15.5, and RP11‐479G22.8, were, respectively, demonstrated to be related with the malignant phenotypes of HCC. Functionally, the six lncRNAs were disclosed to involve in the regulation of multiple cell cycle and stress response‐related pathways via mediating transcription regulation and chromatin modification. In conclusion, our study identified a novel six‐lncRNA signature for resectable HCC prognosis prediction and indicated the underlying mechanisms of HCC progression and the potential functions of the six lncRNAs awaiting further elucidation. By systematic bioinformatics analyses, a novel six‐lncRNA signature including MIR22HG, CTC‐297N7.9, CTD‐2139B15.2, RP11‐589N15.2, RP11‐343N15.5, and RP11‐479G22.8 was established for HCC prognosis prediction and demonstrated to have superior prediction capacity than the two established four‐lncRNA groups and the traditional prognostic TNM stage. Functionally, the six lncRNAs were disclosed to involve in the regulation of multiple cell cycle and stress response‐related pathways via mediating transcription regulation and chromatin modification. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
35. [Treatment options for elderly breast cancer patients over 70 years old]
- Author
-
Bo, Li, Bin, Hua, Xu, Lu, Yue, Chen, and Wen-zheng, Xiao
- Subjects
Aged, 80 and over ,Humans ,Breast Neoplasms ,Female ,Prognosis ,Neoadjuvant Therapy ,Aged ,Neoplasm Staging ,Retrospective Studies - Abstract
To analyze the clinical characteristics and therapeutics of elderly patients with breast carcinomas.A total of 312 patients ( ≥ 70 years old) admitted into Breast Center of Beijing Hospital from September 1997 to September 2011 were included for this retrospective study. Their clinical characteristics, treatment options and prognostic factors were analyzed.They accounted for 14.6% (312/2137) of breast cancer patients treated during the same period. The predominant complaint was palpable mass (n = 250, 80.1%). 90.4% (n = 282) of them were complicated with other diseases. The major pathologic type was invasive ductal carcinoma of non-special type (n = 248, 79.5%). The positive rate of estrogen receptor (ER) and(or) progesterone receptor (PR) was 75.3% (n = 235), and 15.7% (n = 49) cases were Cerb-B2 (+ + +) . The 5, 10-year overall survival were 75.0% and 41.8% respectively. TNM stage, vascular thrombosis, operative regimen and adjuvant therapy were prognostic factors.Surgical operation and endocrine therapy are the first choice remedies for elderly patients. And the major prognostic factors are TNM stage, vascular thrombosis and treatment regimens.
- Published
- 2014
36. Downregulation of LncRNA-RP11-317J10.2 promotes cell proliferation and invasion and predicts poor prognosis in colorectal cancer.
- Author
-
Luo, Jia, Xu, Lu-Ning, Zhang, Sheng-Jun, Jiang, Yi-Gui, Zhuo, De-Xiang, Wu, Lian-Hui, Jiang, Xiang, and Huang, Yue
- Subjects
- *
COLON cancer , *CELL proliferation , *DOWNREGULATION , *NON-coding RNA , *CELL growth - Abstract
Objectives:Using microarray analysis, we previously showed that many lncRNAs are differentially expressed in colorectal cancer (CRC) tissues compared with normal tissues, suggesting that lncRNAs may be involved the initiation and progression of CRC. In this study, we investigated the expression and function of lncRNA-RP11-317J10.2 in human CRC tissues and cell lines. Methods:LncRNA-RP11-317J10.2 expression level was analyzed in 52 colon cancer and cell lines. We used shRNA to knock-down the expression of RP11-317J10.2, and then proliferation assay, colony formation assay, Boyden chamber assay, FACS and Kaplan–Meier survival analysis were performed to explore the biological effect of RP11-317J10.2. Cyclin D1 protein level was detected by Western blot. Results:LncRNA-RP11-317J10.2 is downregulated in CRC and decreased expression is significantly associated with advanced tumor stage, larger tumor size and poor prognosis. RNA interference-mediated knockdown of lncRNA-RP11-317J10.2 in CRC cells promotes G1-to-S cell cycle transition, enhances invasiveness and facilitates cell growthin vitroand in mouse tumor xenograft models. Cyclin D1 was upregulated by lncRNA-RP11-317J10.2 knockdown, and co-expression of cyclin D1-targeting siRNA abrogates the pro-tumorigenic effects of lncRNA-RP11-317J10.2 knockdown. Conclusions:This study reveals a crucial role for lncRNA-RP11-317J10.2 in CRC growth and invasion via upregulation of cyclin D1 expression and suggests that expression of this lncRNA may be a potential prognostic biomarker for CRC. [ABSTRACT FROM PUBLISHER]
- Published
- 2018
- Full Text
- View/download PDF
37. Prognostic Significance of Preoperative Serum Lactate Dehydrogenase in Upper Urinary Tract Urothelial Carcinoma
- Author
-
Xin Ke Zhang, Zhi Ling Zhang, Yun Cao, Xu Lu, Mu Yan Cai, Wan Ming Hu, Chao Nan Qian, Fang Jian Zhou, Jing Ping Yun, and Ping Yang
- Subjects
Male ,0301 basic medicine ,medicine.medical_specialty ,Pathology ,Urology ,Kaplan-Meier Estimate ,Gastroenterology ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Lactate dehydrogenase ,Internal medicine ,medicine ,Humans ,Neoplasm Metastasis ,Stage (cooking) ,Risk factor ,Pathological ,Lymph node ,Aged ,Neoplasm Staging ,Retrospective Studies ,Upper urinary tract ,Carcinoma, Transitional Cell ,L-Lactate Dehydrogenase ,business.industry ,Hazard ratio ,Middle Aged ,Prognosis ,Survival Analysis ,Confidence interval ,030104 developmental biology ,medicine.anatomical_structure ,Urinary Bladder Neoplasms ,Oncology ,chemistry ,030220 oncology & carcinogenesis ,Female ,business - Abstract
Background Upper urinary tract urothelial carcinoma (UUTUC) is one of the uncommon malignancies lacking of prognostic indicators. Lactate dehydrogenase (LDH) has been demonstrated to correlate with clinical outcomes in human cancers. In this study, we aimed to evaluate the prognostic implication of the preoperative LDH in UUTUC. Patients and Methods A cohort of 100 UUTUC samples along with the preoperative LDH value was recruited from January 1990 to June 2011. The cutoff value was set at 245 u/L for the upper value of normal limitation. Univariate and multivariate analyses were conducted to determine the association of LDH with overall survival (OS) and disease-free survival (DFS). Results Kaplan-Meier analysis revealed that high level of LDH (> 245 u/L) was significantly associated with poor OS ( P P = .002). Multivariate Cox proportional analysis indicated LDH, controlled by vascular invasion, pathological stage, lymph node status, subsequent bladder tumor, tumor grade, tumor necrosis, architecture, and multifocality, was as an independent predictor of OS (hazard ratio, 3.181; 95% confidence interval, 1.223-8.276; P = .018) and DFS (hazard ratio, 3.041; 95% confidence interval, 1.247-7.417; P = .015). Stratified showed that elevated serum LDH was correlated with the worse OS in patients without lymph node metastasis ( P = .002) and those at advanced pathological stage ( P Conclusion The preoperative LDH was an independent prognostic factor for patients with UUTUC and could be used as a risk factor to predict the tumor aggressiveness.
- Published
- 2016
38. Treatment options and prognostic risk factors for urachal carcinoma: A multicetnter retrospective study.
- Author
-
Ke, Chunjin, Xu, Lu, Wang, Maoyu, Wang, Yinzhao, Zhou, Qian, Chen, Jinchao, Wang, Zhihua, Wang, Shaogang, Hu, Zhiquan, and Yang, Chunguang
- Abstract
Purpose: Urachal carcinoma (UC) is a rare genitourinary cancer with an insidious onset, high risk of recurrence, and a poor prognosis. Surgical resection alone has difficulty in controlling the tumor. We aim to explore treatment options and prognostic risk factors for UC based on a multicenter cohort and long-term follow-up database.Materials and Methods: The clinical data, treatment and follow-up results of 163 patients with UC in 6 medical centers were analyzed retrospectively. Kaplan-Meier analysis and a Cox proportional hazards model were used to assess the treatment options and prognostic risk factors for UC.Results: Kaplan-Meier analysis showed no difference in the 5-year recurrence-free survival rate (P =0.282) or overall survival rate (P =0.673) between extended partial cystectomy (EPC) and radical cystectomy (RC) for patients at stage III and below. Whether bilateral pelvic lymph nodes were dissected was also not significantly correlated with the patient's recurrence (P =0.921) or prognosis (P =0.741). Postoperative adjuvant chemotherapy significantly reduced the recurrence rate of patients with stage Ⅲb or below (P =0.005). Combined treatment of postoperative recurrence patients prolonged the survival time of patients compared with single chemotherapy or conservative treatment (34.022±5.031 vs. 12.837±2.349 or 6.192±0.875 months, P <0.001). Kaplan-Meier and univariate Cox regression analyses showed that age >55 years, Sheldon stage, carbohydrate antigen 19-9 (CA19-9) >9.935 U/mL, carbohydrate antigen 72-4 (CA724) >6.02 U/mL, and postoperative adjuvant chemotherapy were closely related to the overall survival and recurrence-free survival of patients (P <0.05). Multivariate Cox proportional hazard regression confirmed that the Sheldon stage and CA724 >6.02 U/mL were independent recurrence risk factors.Conclusions: EPC or RC provides similar oncologic results for UC, but bilateral pelvic lymph node dissection is not necessary in early-stage patients. Postoperative adjuvant chemotherapy can significantly reduce the recurrence rate, and combination therapy may provide better survival outcomes. CA724 can predict tumor recurrence or metastasis at an early stage. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
39. Overexpression of trophoblast cell surface antigen 2 as an independent marker for a poor prognosis and as a potential therapeutic target in epithelial ovarian carcinoma.
- Author
-
Xu, Ning, Zhang, Zhihong, Zhu, Jin, Xu, Lu, Li, Yuhua, Duan, Lei, Mao, Yuan, and Li, Hongxia
- Subjects
GENETIC overexpression ,OVARIAN epithelial cancer ,TROPHOBLAST ,CELL surface antigens ,PROTEIN expression ,POLYMERASE chain reaction ,IMMUNOHISTOCHEMISTRY ,PROGNOSIS ,CANCER treatment - Abstract
Most patients with epithelial ovarian cancer ( EOC) are diagnosed at an advanced stage, and therapeutic options for these patients are limited. The identification of suitable biomarkers could be helpful for patients with EOC, who might benefit from targeted therapies even in advanced stages of the disease. Trophoblast cell surface antigen 2 ( TROP2) is highly expressed in various human malignant tumours; however, this has not been demonstrated clearly in EOC. In this study, we further evaluated whether TROP2 is a promising marker for EOC, and thus also a potential target for EOC immunotherapy. Quantitative real-time polymerase chain reaction (qPCR) and fluorescence-activated cell sorting (FACS) analysis were employed to determine TROP2 mRNA and protein expression in both human EOC and normal ovarian cell lines. Additionally, TROP2 protein expression was measured by immunohistochemistry in 128 EOC tissue samples, 21 normal ovarian tissues and 18 normal fallopian tubes. The correlations between TROP2 protein expression and patients' clinicopathological features were investigated, and survival outcomes were analysed. TROP2 mRNA and protein levels were upregulated significantly in EOC cell lines compared with normal cell lines. The protein of TROP2 was expressed in the majority of EOC tissue samples (90.6%) and overexpressed in 75 (58.6%) of the 128 tumour samples. TROP2 overexpression was correlated with relevant clinicopathological characteristics and was associated with significantly shortened overall survival and disease-free survival. Furthermore, TROP2 was an independent prognostic marker for EOCs as analysed by Cox regression. TROP2 was a potential biomarker for targeted therapy in patients with TROP2-overexpressing EOC. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
40. β-catenin mutation is correlated with a favorable prognosis in patients with hepatocellular carcinoma.
- Author
-
ZHENG WANG, YUAN-YUAN SHENG, XIAO-MEI GAO, CHAO-QUN WANG, XIANG-YU WANG, XU LU, JIN-WANG WEI, KAI-LI ZHANG, QIONG-ZHU DONG, and LUN-XIU QIN
- Subjects
LIVER cancer ,CATENIN genetics ,META-analysis ,HETEROGENEITY ,CLINICAL pathology ,HEPATITIS B virus ,PROGNOSIS - Abstract
The β-catenin gene is frequently mutated in patients with hepatocellular carcinoma (HCC) and has long been thought to be one of the major oncogenes involved in the hepatocarcinogenesis. The prognostic role of β-catenin mutation in HCC remains unclear. To address this issue, a search for relevant studies was performed in the PubMed, Embase and Web of Science databases. The pooled effect was calculated from the available data to evaluate the correlation of β-catenin mutation with overall survival rate and tumor clinicopathological features in patients with HCC. The pooled odds ratio (OR) was calculated using the Mantel-Haenszel model for fixed effects. Three studies met the inclusion criteria. A total of 618 cases were included, and β-catenin mutation was identified in 104 of them. The meta-analysis revealed that the presence of β-catenin mutation (n=104), compared with the control group (n=514), was correlated with a longer overall survival rate [OR, 0.33; 95% confidence interval (CI), 0.21-0.53; P<0.00001] in patients with HCC. No significant heterogeneity was found among the eligible studies (I2=0%; P=0.72). β-catenin mutation was correlated with a relatively lower rate of hepatitis B virus infection (OR, 0.36; 95% CI, 0.21-0.61; P=0.0002), improved tumor differentiation (OR, 0.32; 95% CI, 0.19-0.56; P<0.0001) and a lower tumor-node-metastasis stage (I+II) (OR, 0.23; 95% CI, 0.14-0.38; P<0.00001). These findings suggest that β-catenin mutation may predict a favorable prognosis in patients with HCC. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
41. Effects of reduced platelet count on the prognosis for patients with non-small cell lung cancer treated with EGFR-TKI: a retrospective study.
- Author
-
Xu, Lu, Xu, Fangzhou, Kong, Haobo, Zhao, Meiling, Ye, Yuanzi, and Zhang, Yanbei
- Subjects
- *
NON-small-cell lung carcinoma , *PLATELET count , *EPIDERMAL growth factor receptors , *PROTEIN-tyrosine kinases , *LUNG cancer , *PROTEIN kinase inhibitors , *CELL receptors , *LUNG tumors , *RETROSPECTIVE studies , *PROGNOSIS , *RESEARCH funding , *PHARMACODYNAMICS - Abstract
Background: Progressive lung cancer is associated with abnormal coagulation. Platelets play a vital part in evading immune surveillance and angiogenesis in the case of tumor metastasis. The study aimed to analyze the predictive and prognostic effects of platelet count on non-small cell lung cancer (NSCLC) patients treated with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs).Methods: This study retrospectively analyzed the prognostic effects of platelets on 52 NSCLC patients with epidermal growth factor receptor (EGFR) mutant following EGFR-TKI treatment. Related data, together with the progression-free survival (PFS) and overall survival (OS) were collected before and after 2 cycles of treatments (60 days).Results: The anti-EGFR treatment markedly reduced the platelet count in 33 (63.5%) patients after 2 cycles of treatment. Multivariate Cox analysis revealed that, the decreased platelet count was closely correlated with the longer OS (HR = 0.293; 95%CI: 0.107-0.799; p = 0.017). Besides, the median OS was 326 days in the decreased platelet count group and 241 days in the increased platelet count group (HR = 0.311; 95%CI: 0.118-0.818; P = 0.018), as obtained from the independent baseline platelet levels and other clinical features.Conclusions: The platelet count may predict the prognosis for EGFR-TKI treatment without additional costs. Besides, changes in platelet count may serve as a meaningful parameter to establish the prognostic model for NSCLC patients receiving anti-EGFR targeted therapy. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
42. Impact of visceral adiposity on severity of acute pancreatitis: a propensity score-matched analysis.
- Author
-
Xie, Jiarong, Xu, Lu, Pan, Yuning, Li, Peifei, Liu, Yi, Pan, Yue, and Xu, Lei
- Subjects
- *
APACHE (Disease classification system) , *SYSTEMIC inflammatory response syndrome , *PROPORTIONAL hazards models , *RECEIVER operating characteristic curves , *PANCREATITIS , *ADIPOSE tissues , *CLINICAL trials , *COMPUTED tomography , *PROBABILITY theory , *PROGNOSIS , *RESEARCH funding , *ACUTE diseases , *SKELETAL muscle - Abstract
Background: The relationship between visceral adiposity and acute pancreatitis (AP) has not been completely elucidated. This study evaluated the significance of visceral adipose tissue (VAT) and the ratio of VAT to skeletal muscle tissue (VAT/SMT) in the prognosis of AP patients.Methods: Based on a 1:2 propensity score matching, 306 hospitalized patients were enrolled in the study analysis from 2010 to 2017. VAT, subcutaneous adipose tissue (SAT), and SMT were measured using unenhanced computed tomography (CT). Cox proportional hazards models were applied for the analysis.Results: VAT and the VAT/SMT ratio were significantly higher in the severe AP (SAP) and moderately severe AP (MSAP) groups compared to the mild AP (MAP) group (both p < 0.001). Intensive care transfer, AP severity, systemic complications, and prognostic scores (Acute Physiology and Chronic Health Evaluation II [APACHE-II] score ≥ 8, Ranson's score ≥ 3, Bedside Index of Severity in Acute Pancreatitis [BISAP] score ≥ 3, and the systemic inflammatory response syndrome [SIRS] score ≥ 2) significantly correlated with VAT and the VAT/SMT ratio in AP patients. The multivariate adjusted hazard ratios (HRs) for VAT and the VAT/SMT ratio in the relationship of body parameters and AP mortality were 1.042 (95% confidence interval (CI), 1.019-1.066) and 7.820 (95% CI, 1.978-30.917), respectively. Compared with other prognostic scores, VAT had the highest area under the curve of receiver operating characteristics (ROC) (0.943, 95% CI, 0.909-0.976).Conclusion: High VAT and VAT/SMT ratio are independent negative prognostic indicators of AP.Trial Registration: Clinical study registration number: NCT03482921 . Date of registration: 03/23/2018. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
43. MicroRNA expression profiles predict clinical phenotypes and prognosis in chromophobe renal cell carcinoma.
- Author
-
Ge, Yu-Zheng, Xin, Hui, Lu, Tian-Ze, Xu, Zheng, Yu, Peng, Zhao, You-Cai, Li, Ming-Hao, Zhao, Yan, Zhong, Bing, Xu, Xiao, Zhou, Liu-Hua, Wu, Ran, Xu, Lu-Wei, Wu, Jian-Ping, Li, Wen-Cheng, Zhu, Jia-Geng, and Jia, Rui-Peng
- Subjects
MICRORNA ,RENAL cell carcinoma ,PHENOTYPES ,PROGNOSIS ,GENE expression ,DISEASE progression ,PROGRESSION-free survival - Abstract
Chromophobe renal cell carcinoma (chRCC) is the third most common subtype of kidney cancers. In the present study, we identified 58 treatment-naïve primary chRCC patients from The Cancer Genome Atlas dataset and analyzed the genome-wide microRNA (miRNA) expression profiles, with the aim to assess the relationship of miRNA expression with the progression and prognosis of chRCC. Overall, a total of 105 miRNAs were found to be differentially expressed between tumor and the adjacent normal tissues from 22 chRCC patients. In the unpaired condition (58 chRCC vs. 22 normal tissues), 77 (96.3%) samples were distinguished correctly by the signatures. In the progression-related profiles, 27 miRNAs were selected for pathologic T and 9 for lymph node involvement. In the survival analyses, the expression levels of mir-191, mir-19a, mir-210, and mir-425 were significantly associated with both recurrence-free survival (RFS) and overall survival, while mir-210 was proven as an independent prognostic factor in terms of RFS. In summary, miRNAs are expressed differentially in chRCC, and unique expression of miRNAs is associated with the progression and prognosis of chRCC. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
44. Prognostic value of long non-coding RNA FOXD2-AS1 expression in patients with solid tumors.
- Author
-
Zhou, Lu, Li, Zhi, Shao, Xinye, Yang, Bowen, Feng, Jing, Xu, Lu, and Teng, Yuee
- Subjects
- *
BREAST cancer prognosis , *NON-coding RNA , *PROGRESSION-free survival , *CANCER prognosis , *TUMORS , *ONLINE databases - Abstract
Although increasing evidence has revealed that FOXD2-AS1 overexpression exists in various solid tumors, the value of FOXD2-AS1 as a prognostic marker in such cancers remains uncertain. Accordingly, the present research aimed to assess the association of FOXD2-AS1 with cancer prognosis and predict the biological function of FOXD2-AS1. We systematically retrieved PubMed, PMC, Web of Science, EMBASE and Wiley Online Library databases for eligible articles published up to December 2018. Pooled hazard ratios (HRs) and odds ratios (ORs) with 95% confidence intervals (95%CIs) were calculated to evaluate the correlation of FOXD2-AS1 expression with overall survival (OS), disease free survival (DFS) and clinicopathological characteristics. We also used five Gene Expression Omnibus (GEO) datasets from breast cancer patients to explore the relationship between FOXD2-AS1 expression and prognosis. Finally, we validated FOXD2-AS1 expression in various carcinomas and predicted its biological function based on the public databases. A total of 13 studies with 2502 tumor patients were included. The pooled HRs demonstrated that FOXD2-AS1 overexpression was significantly associated with unfavorable OS (HR = 1.39, 95%CI: 1.23–1.57, p < 0.001) and DFS (HR = 2.24, 95%CI: 1.55–3.23, p < 0.001) in tumor patients. The pooled ORs indicated that FOXD2-AS1 upregulation was related to large tumor size (OR = 1.53, 95%CI: 1.26–1.85, p < 0.001), deep invasion depth (OR = 1.99, 95%CI: 1.53–2.58, p < 0.001), distant metastasis (OR = 2.03, 95%CI: 1.69–2.43, p < 0.001) and advanced TNM stage (OR = 1.35, 95%CI: 1.06–1.72, p = 0.0150), but not to lymph node metastasis nor differentiation. Moreover, a similar pooled result for the OS of breast cancer patients was obtained (HR = 1.55, 95%CI: 1.14–2.11, p = 0.0052) by analyzing GEO data. Finally, elevated FOXD2-AS1 expression in various solid tumor tissues was verified based on The Cancer Genome Atlas (TCGA) data. Further functional prediction demonstrated that FOXD2-AS1 may participate in some cancer-related pathways. Elevated FOXD2-AS1 expression was associated with poor survival in patients with solid tumors and may serve as a potential prognostic biomarker for a variety of cancers. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.